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1. INTRODUCTION {#jmv25614-sec-0010}
===============

The hepatitis C virus (HCV) is a major global health challenge.[1](#jmv25614-bib-0001){ref-type="ref"} An estimated 20% of all individuals chronically infected with HCV are residing in the Middle East and North Africa (MENA).[2](#jmv25614-bib-0002){ref-type="ref"}, [3](#jmv25614-bib-0003){ref-type="ref"} Chronic HCV infection leads to various morbidities, such as liver fibrosis, cirrhosis, and cancer,[4](#jmv25614-bib-0004){ref-type="ref"} all of which strains healthcare systems.[5](#jmv25614-bib-0005){ref-type="ref"}

HCV displays extensive genetic diversity and is categorized into seven genotypes (numbered from 1 to 7).[6](#jmv25614-bib-0006){ref-type="ref"} Although genotypes 1 and 3 are common worldwide,[6](#jmv25614-bib-0006){ref-type="ref"} genotype distribution can vary from one geographical area to another.[6](#jmv25614-bib-0006){ref-type="ref"}, [7](#jmv25614-bib-0007){ref-type="ref"} Specific HCV genotypes have been hypothesized to be associated with specific modes of acquisition, or with specific populations.[6](#jmv25614-bib-0006){ref-type="ref"}, [7](#jmv25614-bib-0007){ref-type="ref"}, [8](#jmv25614-bib-0008){ref-type="ref"} However, any specific genotype circulating within a specific population tends also to be reflective of the circulating genotypes in the wider population of that country.[7](#jmv25614-bib-0007){ref-type="ref"}

Delineating the epidemiology of HCV genotypes is critical as it can convey inferences about the modes of transmission and their dynamics in a given population.[6](#jmv25614-bib-0006){ref-type="ref"}, [9](#jmv25614-bib-0009){ref-type="ref"} Despite this, existing studies tend to be descriptive and qualitative in nature.[6](#jmv25614-bib-0006){ref-type="ref"}, [7](#jmv25614-bib-0007){ref-type="ref"}, [8](#jmv25614-bib-0008){ref-type="ref"} Against this background, we aimed to demonstrate, to our knowledge for the first time, an analytical and quantitative approach to investigate the epidemiology of HCV genotypes, through meta‐regressions, as applied to HCV genotype distribution in MENA. This study is part of the MENA HCV Epidemiology Synthesis Project, an ongoing endeavor to delineate HCV epidemiology and inform key public health research, policy, and programming priorities in MENA.[7](#jmv25614-bib-0007){ref-type="ref"}, [10](#jmv25614-bib-0010){ref-type="ref"}, [11](#jmv25614-bib-0011){ref-type="ref"}, [12](#jmv25614-bib-0012){ref-type="ref"}, [13](#jmv25614-bib-0013){ref-type="ref"}, [14](#jmv25614-bib-0014){ref-type="ref"}, [15](#jmv25614-bib-0015){ref-type="ref"}, [16](#jmv25614-bib-0016){ref-type="ref"}, [17](#jmv25614-bib-0017){ref-type="ref"}, [18](#jmv25614-bib-0018){ref-type="ref"}, [19](#jmv25614-bib-0019){ref-type="ref"}, [20](#jmv25614-bib-0020){ref-type="ref"}, [21](#jmv25614-bib-0021){ref-type="ref"}, [22](#jmv25614-bib-0022){ref-type="ref"}, [23](#jmv25614-bib-0023){ref-type="ref"}, [24](#jmv25614-bib-0024){ref-type="ref"}, [25](#jmv25614-bib-0025){ref-type="ref"}, [26](#jmv25614-bib-0026){ref-type="ref"}

2. METHODS {#jmv25614-sec-0020}
==========

Studies reporting HCV genotype data were retrieved from the MENA HCV Epidemiology Synthesis Project database,[2](#jmv25614-bib-0002){ref-type="ref"} originally for an earlier study of HCV genotypes in MENA.[7](#jmv25614-bib-0007){ref-type="ref"} This comprehensive database consists of several subdatabases on different HCV epidemiological measures, and was populated through a series of systematic reviews for HCV infection across MENA.[10](#jmv25614-bib-0010){ref-type="ref"}, [11](#jmv25614-bib-0011){ref-type="ref"}, [12](#jmv25614-bib-0012){ref-type="ref"}, [13](#jmv25614-bib-0013){ref-type="ref"}, [14](#jmv25614-bib-0014){ref-type="ref"}, [15](#jmv25614-bib-0015){ref-type="ref"}, [16](#jmv25614-bib-0016){ref-type="ref"}, [17](#jmv25614-bib-0017){ref-type="ref"}, [26](#jmv25614-bib-0026){ref-type="ref"} The reviews followed the same methodology, informed by the Cochrane Collaboration handbook,[27](#jmv25614-bib-0027){ref-type="ref"} and used the Preferred Reporting Items for Systematic reviews and Meta‐analyses (PRISMA) guidelines[28](#jmv25614-bib-0028){ref-type="ref"} to report their findings.

In these reviews, genotype information were extracted from individual studies to populate the HCV genotype subdatabase. Participants with untypeable genotype were removed from the sample size of the study. Participants with mixed genotypes contributed separately to the quantification of each genotype. The population of each study was classified into six risk categories based on the exposure risk to HCV infection, as presented in Figure [1](#jmv25614-fig-0001){ref-type="fig"} and as informed by existing literature[29](#jmv25614-bib-0029){ref-type="ref"}, [30](#jmv25614-bib-0030){ref-type="ref"}, [31](#jmv25614-bib-0031){ref-type="ref"} and our earlier studies.[10](#jmv25614-bib-0010){ref-type="ref"}, [11](#jmv25614-bib-0011){ref-type="ref"}, [12](#jmv25614-bib-0012){ref-type="ref"}, [13](#jmv25614-bib-0013){ref-type="ref"}, [14](#jmv25614-bib-0014){ref-type="ref"}, [15](#jmv25614-bib-0015){ref-type="ref"}, [16](#jmv25614-bib-0016){ref-type="ref"}, [17](#jmv25614-bib-0017){ref-type="ref"}, [26](#jmv25614-bib-0026){ref-type="ref"} A total of 175 genotype studies on 15 960 participants were included.

![Population classification into categories by risk of exposures to hepatitis C virus (HCV) infection](JMV-92-386-g001){#jmv25614-fig-0001}

Univariable and multivariable random effects meta‐regressions were conducted for the proportion of each HCV genotype, based on established statistical methodology,[27](#jmv25614-bib-0027){ref-type="ref"} to assess the association between genotype and each of country/subregion and population classification. Variables with a likelihood ratio test *P* \< .2 in the univariable analysis qualified for inclusion in the multivariable analysis. Relative risks and adjusted relative risks (ARRs) with a *P* value between .05 and .10 in the multivariable model, for any association between genotype and a given factor, indicated *good evidence* for the association. *P* ≤ .05 indicated *strong evidence* for the association.

3. RESULTS {#jmv25614-sec-0030}
==========

The results of the meta‐regressions are shown in Table [1](#jmv25614-tbl-0001){ref-type="table"} with key results described in the following subsections.

###### 

Univariable and multivariable meta‐regression models for hepatitis C virus (HCV) genotypes in the Middle East and North Africa (MENA)

                                                                   Number of studies    Univariable analysis   Multivariable analysis                                                                                                     
  ---------------------------------------------------------------- -------------------- ---------------------- ------------------------ -------- ------ ------------------- -------- ---------------------------------------------------- --
  **Genotype 1**                                                                                                                                                                                                                          
  Population classification                                        General population   32                     1                        ⋯                                   1        ⋯                                                    
  High‐risk clinical populations                                   63                   2.0 (1.4‐3.0)          \<.001                                   1.2 (1.0‐1.5)       .098                                                          
  Populations at intermediate risk                                 16                   0.8 (0.4‐1.6)          .605                                     1.0 (0.7‐1.4)       .927                                                          
  Populations with liver‐related conditions                        28                   0.6 (0.3‐0.9)          .018                                     1.1 (0.8‐1.4)       .619                                                          
  PWID                                                             13                   1.2 (0.7‐2.1)          .569                                     0.9 (0.6‐1.2)       .378                                                          
  Special clinical populations                                     13                   1.5 (0.8‐3.1)          .210                                     1.3 (0.9‐1.9)       .229                                                          
  Mixed populations                                                10                   1.1 (0.6‐2.1)          .784                     \<.001   22.0   0.9 (0.6‐1.2)       .367                                                          
  Country/subregion                                                Egypt                38                     1                        ⋯                                   1        ⋯                                                    
  Afghanistan                                                      3                    5.5 (3.0‐10.3)         \<.001                                   6.5 (3.3‐12.8)      \<.001                                                        
  Gulf[^a^](#jmv25614-tbl1-note-0002){ref-type="fn"}               11                   6.8 (4.7‐9.8)          \<.001                                   6.1 (4.1‐9.0)       \<.001                                                        
  Iran                                                             33                   7.7 (5.9‐10.2)         \<.001                                   7.2 (5.4‐9.6)       \<.001                                                        
  Fertile Crescent[^b^](#jmv25614-tbl1-note-0003){ref-type="fn"}   45                   5.7 (4.3‐7.5)          \<.001                                   5.3 (4.0‐7.1)       \<.001                                                        
  Maghreb[^c^](#jmv25614-tbl1-note-0004){ref-type="fn"}            29                   10.8 (8.3‐14.2)        \<.001                                   10.2 (7.7‐13.5)     \<.001                                                        
  Pakistan                                                         16                   1.4 (1.0‐2.0)          .075                     \<.001   83.1   1.3 (0.9‐1.9)       .111     84.4[^d^](#jmv25614-tbl1-note-0005){ref-type="fn"}   
  **Genotype 2**                                                                                                                                                                                                                          
  Population classification                                        General population   32                     1                        ⋯                                   1        ⋯                                                    
  High‐risk clinical populations                                   63                   2.9 (1.2‐7.0)          .020                                     2.3 (1.0‐5.5)       .056                                                          
  Populations at intermediate risk                                 16                   3.9 (1.2‐12.6)         .025                                     5.1 (1.7‐15.7)      .005                                                          
  Populations with liver‐related conditions                        28                   1.6 (0.6‐4.5)          .364                                     1.4 (0.5‐3.8)       .465                                                          
  PWID                                                             13                   2.9 (0.8‐10.5)         .110                                     2.9 (0.9‐10.0)      .086                                                          
  Special clinical populations                                     13                   1.3 (0.3‐7.0)          .720                                     1.0 (0.2‐5.3)       .961                                                          
  Mixed populations                                                10                   3.1 (0.9‐11.0)         .075                     .176     3.0    3.0 (0.9‐9.6)       .069                                                          
  Country/subregion                                                Egypt                38                     1                        ⋯                                   1        ⋯                                                    
  Afghanistan                                                      3                    0.6 (0.0‐25.4)         .774                                     0.4 (0.0‐21.6)      .668                                                          
  Gulf[^a^](#jmv25614-tbl1-note-0002){ref-type="fn"}               11                   3.8 (1.2‐11.9)         .021                                     5.0 (1.4‐17.3)      .012                                                          
  Iran                                                             33                   1.4 (0.5‐3.5)          .512                                     1.4 (0.5‐4.0)       .576                                                          
  Fertile Crescent[^b^](#jmv25614-tbl1-note-0003){ref-type="fn"}   45                   3.4 (1.3‐8.9)          .011                                     3.4 (1.3‐9.2)       .017                                                          
  Maghreb[^c^](#jmv25614-tbl1-note-0004){ref-type="fn"}            29                   7.4 (3.0‐18.0)         \<.001                                   7.1 (2.6‐19.2)      \<.001                                                        
  Pakistan                                                         16                   3.6 (1.4‐9.5)          .009                     \<.001   23.2   4.8 (1.7‐13.6)      .003     28.8[^d^](#jmv25614-tbl1-note-0005){ref-type="fn"}   
  **Genotype 3**                                                                                                                                                                                                                          
  Population classification                                        General population   32                     1                        ⋯                                   1        ⋯                                                    
  High‐risk clinical populations                                   63                   1.0 (0.5‐2.2)          .983                                     0.9 (0.6‐1.4)       .646                                                          
  Populations at intermediate risk                                 16                   0.6 (0.2‐2.2)          .430                                     1.9 (0.8‐4.2)       .124                                                          
  Populations with liver‐related conditions                        28                   1.4 (0.5‐3.7)          .486                                     1.3 (0.7‐2.4)       .330                                                          
  PWID                                                             13                   3.1 (1.1‐8.5)          .029                                     1.7 (1.0‐3.0)       .074                                                          
  Special clinical populations                                     13                   0.8 (0.2‐3.4)          .745                                     1.4 (0.5‐3.7)       .518                                                          
  Mixed populations                                                10                   0.5 (0.1‐1.6)          .228                     .055     13.2   0.8 (0.4‐1.6)       .525                                                          
  Country/subregion                                                Egypt                38                     1                        ⋯                                   1        ⋯                                                    
  Afghanistan                                                      3                    60.9 (21.5‐172.3)      \<.001                                   45.4 (14.3‐143.8)   \<.001                                                        
  Gulf[^a^](#jmv25614-tbl1-note-0002){ref-type="fn"}               11                   7.5 (2.5‐22.9)         \<.001                                   7.5 (2.3‐24.6)      \<.001                                                        
  Iran                                                             33                   33.8 (15.6‐73.0)       \<.001                                   43.9 (18.9‐101.8)   \<.001                                                        
  Fertile Crescent[^b^](#jmv25614-tbl1-note-0003){ref-type="fn"}   45                   9.2 (4.0‐21.2)         \<.001                                   11.2 (4.6‐27.0)     \<.001                                                        
  Maghreb[^c^](#jmv25614-tbl1-note-0004){ref-type="fn"}            29                   4.4 (1.9‐10.3)         \<.001                                   5.4 (2.2‐13.1)      \<.001                                                        
  Pakistan                                                         16                   71.7 (32.4‐158.9)      \<.001                   \<.001   77.0   69.6 (31.2‐155.5)   \<.001   77.9[^d^](#jmv25614-tbl1-note-0005){ref-type="fn"}   
  **Genotype 4**                                                                                                                                                                                                                          
  Population classification                                        General population   32                     1                        ⋯                                   1        ⋯                                                    
  High‐risk clinical populations                                   63                   0.3 (0.2‐0.7)          .004                                     0.8 (0.6‐1.1)       .250                                                          
  Populations at intermediate risk                                 16                   1.3 (0.5‐3.5)          .580                                     1.0 (0.7‐1.5)       .915                                                          
  Populations with liver‐related conditions                        28                   0.8 (0.4‐1.9)          .654                                     1.0 (0.7‐1.3)       .957                                                          
  PWID                                                             13                   0.4 (0.1‐1.2)          .104                                     1.0 (0.6‐1.7)       .851                                                          
  Special clinical populations                                     13                   1.3 (0.5‐3.9)          .583                                     1.0 (0.7‐1.5)       .985                                                          
  Mixed populations                                                10                   0.6 (0.2‐1.8)          .341                     .007     9.9    0.8 (0.5‐1.3)       .348                                                          
  Country/subregion                                                Egypt                38                     1                        ⋯                                   1        ⋯                                                    
  Afghanistan                                                      3                    0.0 (0.0‐0.5)          .023                                     0.0 (0.0‐0.5)       .021                                                          
  Gulf[^a^](#jmv25614-tbl1-note-0002){ref-type="fn"}               11                   0.5 (0.4‐0.7)          \<.001                                   0.5 (0.3‐0.8)       .002                                                          
  Iran                                                             33                   0.0 (0.0‐0.0)          \<.001                                   0.0 (0.0‐0.1)       \<.001                                                        
  Fertile Crescent[^b^](#jmv25614-tbl1-note-0003){ref-type="fn"}   45                   0.6 (0.5‐0.8)          \<.001                                   0.6 (0.5‐0.8)       \<.001                                                        
  Maghreb[^c^](#jmv25614-tbl1-note-0004){ref-type="fn"}            29                   0.1 (0.1‐0.1)          \<.001                                   0.1 (0.1‐0.1)       \<.001                                                        
  Pakistan                                                         16                   0.0 (0.0‐0.1)          \<.001                   \<.001   91.1   0.0 (0.0‐0.1)       \<.001   90.3[^d^](#jmv25614-tbl1-note-0005){ref-type="fn"}   
  **Genotype 5**                                                                                                                                                                                                                          
  Population classification                                        General population   32                     1                        ⋯                                   1        ⋯                                                    
  High‐risk clinical populations                                   63                   0.3 (0.1‐1.0)          .055                                     0.3 (0.1‐1.2)       .087                                                          
  Populations at intermediate risk                                 16                   0.6 (0.1‐3.7)          .540                                     0.7 (0.1‐4.6)       .694                                                          
  Populations with liver‐related conditions                        28                   0.7 (0.2‐2.7)          .594                                     1.0 (0.2‐4.2)       .956                                                          
  PWID                                                             13                   1.1 (0.2‐5.7)          .875                                     1.9 (0.3‐10.9)      .478                                                          
  Special clinical populations                                     13                   6.6 (1.4‐30.2)         .015                                     12.2 (2.4‐62.7)     .003                                                          
  Mixed populations                                                10                   0.1 (0.0‐0.8)          .031                     \<.001   45.9   0.2 (0.0‐1.2)       .080                                                          
  Country/subregion                                                Egypt                38                     1                        ⋯                                   1        ⋯                                                    
  Afghanistan                                                      3                    1.7 (0.0‐86.2)         .778                                     1.0 (0.0‐59.0)      .995                                                          
  Gulf[^a^](#jmv25614-tbl1-note-0002){ref-type="fn"}               11                   3.3 (0.6‐18.9)         .187                                     1.1 (0.2‐5.7)       .945                                                          
  Iran                                                             33                   0.5 (0.1‐2.1)          .323                                     0.9 (0.2‐4.5)       .929                                                          
  Fertile Crescent[^b^](#jmv25614-tbl1-note-0003){ref-type="fn"}   45                   2.3 (0.6‐8.5)          .227                                     4.7 (1.2‐17.6)      .024                                                          
  Maghreb[^c^](#jmv25614-tbl1-note-0004){ref-type="fn"}            29                   0.5 (0.1‐2.1)          .313                                     1.1 (0.2‐5.5)       .881                                                          
  Pakistan                                                         16                   0.9 (0.2‐4.5)          .940                     .157     11.5   1.2 (0.3‐5.8)       .789     57.3[^d^](#jmv25614-tbl1-note-0005){ref-type="fn"}   

Abbreviations: ARR, adjusted relative risk; CI, confidence interval; LR, likelihood ratio; PWID, people who inject drugs; RR, relative risk.

Countries include Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and United Arab Emirates.

Countries include Iraq, Jordan, Lebanon, Palestine, and Syria.

Countries include Algeria, Libya, Mauritania, Morocco, and Tunisia.

The adjusted R‐squared for the full model.

John Wiley & Sons, Ltd.

3.1. Genotype 1 {#jmv25614-sec-0040}
---------------

There was strong evidence for variation in genotype 1 distribution by country/subregion, and good evidence for variation by population. Relative to Egypt, all countries/subregions had much higher presence of genotype 1, apart from Pakistan. Genotype 1 was also more present in high‐risk clinical populations (ARR of 1.2 \[95% confidence interval \[CI\]:1.0‐1.5\]) than in the general population. Country/subregion and population explained the vast majority of the variation in genotype 1 distribution (84.4%), mostly through the country/subregion variable.

3.2. Genotype 2 {#jmv25614-sec-0050}
---------------

There was strong evidence for variation in genotype 2 distribution by country/subregion and by population. Relative to Egypt, the Gulf, Fertile Crescent, Maghreb, and Pakistan had higher presence of genotype 2. Genotype 2 was also more present in high‐risk clinical populations, populations at intermediate risk, and people who inject drugs (PWID), relative to the general population. Country/subregion and population explained only 28.8% of the variation in genotype 2 distribution, mostly through the country/subregion variable, with most variation remaining unexplained.

3.3. Genotype 3 {#jmv25614-sec-0060}
---------------

There was strong evidence for variation in genotype 3 distribution by country/subregion, and good evidence for variation by population. Relative to Egypt, all countries/subregions had substantially higher presence of genotype 3. This was particularly so for Afghanistan, Iran, and Pakistan, that had much higher presence of this genotype. Genotype 3 was also more present in PWID (ARR of 1.7 \[95% CI: 1.0‐3.0\]) than in the general population. Country/subregion and population explained the vast majority of the variation in genotype 3 distribution (77.9%), mostly through the country/subregion variable.

A sensitivity analysis (Table S1) was performed in which the meta‐regressions were performed excluding countries in which genotype 3 was the most dominant genotype (Afghanistan and Pakistan but not Iran[7](#jmv25614-bib-0007){ref-type="ref"}). The analysis was conducted to assess the purported global association between this genotype and PWID.[6](#jmv25614-bib-0006){ref-type="ref"} It was found that there is indeed strong evidence for an association between this genotype and PWID (ARR of 2.7 \[95% CI: 1.2‐5.8\]). The sensitivity analysis also confirmed the strong evidence for variation by country/subregion---country/subregion and population explained the majority of the variation (66.4%), mostly through the country/subregion variable.

3.4. Genotype 4 {#jmv25614-sec-0070}
---------------

There was strong evidence for variation in genotype 4 distribution by country/subregion, with most countries having substantially lower (Gulf and Fertile Crescent), or much lower (Afghanistan, Iran, Maghreb, and Pakistan) presence of this genotype compared with Egypt. No significant evidence was found for variation in genotype 4 distribution by population, probably reflecting the broadly disseminated nature of the genotype 4 epidemic in Egypt.[7](#jmv25614-bib-0007){ref-type="ref"}, [10](#jmv25614-bib-0010){ref-type="ref"} Country/subregion and population explained the vast majority of the variation in genotype 4 distribution (90.3%), nearly all of which through the country/subregion variable.

3.5. Genotype 5 {#jmv25614-sec-0080}
---------------

Unlike the other genotypes, most of the variation in the distribution of genotype 5 was explained by the population variable, rather than the country/subregion variable. Paradoxically also, compared with the general population, there was strong evidence for *higher* presence of this genotype in special clinical populations, but *lower* presence in high‐risk clinical populations. Moreover, of all countries/subregions, only the Fertile Crescent had higher presence of genotype 5 relative to Egypt. Population and country/subregion explained 57.3% of the variation in genotype 5 distribution. These results, which are epidemiologically not easy to interpret, could be an artifact of the very low presence of this genotype in the MENA region.[7](#jmv25614-bib-0007){ref-type="ref"} Genotype 5 was identified in only 3.9% of all genotype studies, with only 0.1% of infections being with this genotype.

3.6. Genotype 6 and genotype 7 {#jmv25614-sec-0090}
------------------------------

There were too few studies in which genotype 6 was identified (1.7%), resulting in very broad confidence intervals of limited implications, thus no analyses are reported for this genotype. No study identified the presence of genotype 7 in MENA.

4. DISCUSSION {#jmv25614-sec-0100}
=============

We used a quantitative analytical approach to investigate epidemiological associations for HCV genotypes, with application to the MENA region. The utility of this approach was demonstrated---the study yielded estimates for the differences in genotype distributions by country/subregion and by population type. Overall, country/subregion explained most of the variation, highlighting geography as the *principal* determinant of genotype distribution. Interestingly, we found evidence for an association between genotype 1 and high‐risk clinical populations, possibly explaining, with the global presence of these populations, the common presence of this genotype across countries.[6](#jmv25614-bib-0006){ref-type="ref"} This finding also supports existing literature suggesting such an association.[6](#jmv25614-bib-0006){ref-type="ref"} We further found an association between genotype 3 and PWID, thereby supporting an apparently global role for this genotype in HCV transmission through injecting drug use.[6](#jmv25614-bib-0006){ref-type="ref"} While these findings were generated for MENA, they may reflect generic results of global relevance.

Genotype epidemiology in the region may have been influenced by several factors. The importation of contaminated blood products, before the onset of blood screening, primarily from Western countries, has been linked to a fraction of reported HIV cases,[32](#jmv25614-bib-0032){ref-type="ref"}, [33](#jmv25614-bib-0033){ref-type="ref"} and presumably helped disseminate HCV genotype 1 across the region.[6](#jmv25614-bib-0006){ref-type="ref"} Genotype 1 was ubiquitous across most countries and subregions of MENA, which may also be attributed to population movement links to countries outside of MENA, as genotype 1 is the most common genotype globally.[6](#jmv25614-bib-0006){ref-type="ref"}, [30](#jmv25614-bib-0030){ref-type="ref"} For example, the presence of genotype 1 was highest in the Maghreb subregion, almost 11‐fold higher than in Egypt, a subregion which has strong migration links with western and southern Europe.[34](#jmv25614-bib-0034){ref-type="ref"}, [35](#jmv25614-bib-0035){ref-type="ref"}

The emerging HIV epidemics among PWID in MENA, and specifically in Afghanistan, Iran, and Pakistan, have been linked to overlapping injecting networks across these countries.[36](#jmv25614-bib-0036){ref-type="ref"}, [37](#jmv25614-bib-0037){ref-type="ref"}, [38](#jmv25614-bib-0038){ref-type="ref"} This may have (partially) contributed to the relatively larger presence of genotype 3 among PWID in these countries. A strong presence of genotype 4 was found in Egypt. Phylogenetic evidence has shown that genotype 4 in this country originated from central Africa,[39](#jmv25614-bib-0039){ref-type="ref"} and circulated endemically until the mass expansion of the HCV epidemic through the parenteral antischistosomal therapy (PAT) campaigns and other healthcare practices.[10](#jmv25614-bib-0010){ref-type="ref"}, [11](#jmv25614-bib-0011){ref-type="ref"}, [39](#jmv25614-bib-0039){ref-type="ref"}, [40](#jmv25614-bib-0040){ref-type="ref"}, [41](#jmv25614-bib-0041){ref-type="ref"}, [42](#jmv25614-bib-0042){ref-type="ref"}, [43](#jmv25614-bib-0043){ref-type="ref"} Genotype 4 was also found to be present in countries that host large migrant labor populations from Egypt,[44](#jmv25614-bib-0044){ref-type="ref"} such as in countries of the Fertile Crescent[13](#jmv25614-bib-0013){ref-type="ref"} and Gulf[26](#jmv25614-bib-0026){ref-type="ref"} subregions of MENA.[7](#jmv25614-bib-0007){ref-type="ref"}, [18](#jmv25614-bib-0018){ref-type="ref"}

This study had limitations. HCV genotype data were not available for several countries. The number of studies also varied by population type and country/subregion, and the sample size of genotyped individuals was small for a number of studies---we may not have had sufficient statistical power to discern specific associations. This may explain the lack of a clear interpretation/identification of epidemiological associations for genotype 5. We assessed associations for specific key factors that were available in extracted data, but we were unable to assess the role of a broader set of factors. This may clarify why most variation in genotype 2 distribution remained unexplained. Despite these limitations, we were able to utilize a breadth of genotype data that was systematically gathered and that allowed us to conduct such analysis, yielding relevant inferences about genotype distribution and HCV transmission dynamics.

In conclusion, geography appears to be the principal determinant of HCV genotype distribution. Genotype 1 is associated with transmission through high‐risk clinical procedures, such as blood transfusions, hemodialysis, and medical injections; while genotype 3 is associated with transmission through injecting drug use. These findings demonstrate the power of such an analytical approach, which if extended to other regions and globally, may yield relevant epidemiological inferences that can inform control and treatment programs.
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